Fig. 3From: The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signalingBsAbs simultaneously targeting two immunoinhibitory molecules on tumor cells or cytokines in the TME. In contrast to BiTEs, these bispecific antibodies aim to block two immunoinhibitory signaling pathways (except 4-1BB agonist antibodies), generating synergistic anti-cancer effects or minimizing drug resistance (Created with Biorender)Back to article page